;PMID: 2384072
;source_file_895.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..143] = [t:50..143]
;2)section:[e:147..173] = [t:147..173]
;3)section:[e:177..260] = [t:177..260]
;4)sentence:[e:264..506] = [t:264..506]
;5)sentence:[e:507..656] = [t:507..656]
;6)sentence:[e:657..902] = [t:657..902]
;7)sentence:[e:903..1016] = [t:903..1016]
;8)sentence:[e:1017..1121] = [t:1017..1121]
;9)sentence:[e:1122..1301] = [t:1122..1301]
;10)sentence:[e:1302..1538] = [t:1302..1538]
;11)section:[e:1542..1586] = [t:1542..1586]

;section 0 Span:0..44
;Environ Health Perspect. 1990 Apr;85:95-100.
(SEC
  (FRAG (NNP:[0..7] Environ) (NNP:[8..14] Health) (NNP:[15..23] Perspect)
        (.:[23..24] .) (CD:[25..29] 1990) (IN:[30..36] Apr;85) (CD:[36..39] :95)
        (::[39..40] -) (CD:[40..43] 100) (.:[43..44] .)))

;sentence 1 Span:50..143
;Protection against chemical-induced lung injury by inhibition of pulmonary 
;cytochrome P-450.
;[69..77]:substance:"chemical"
;[126..142]:cyp450:"cytochrome P-450"
(SENT
  (NP-HLN
    (NP (NN:[50..60] Protection))
    (PP (IN:[61..68] against)
      (NP
        (ADJP (NN:[69..77] chemical) (HYPH:[77..78] -) (VBN:[78..85] induced))
        (NN:[86..90] lung) (NN:[91..97] injury)))
    (PP (IN:[98..100] by)
      (NP
        (NP (NN:[101..111] inhibition))
        (PP (IN:[112..114] of)
          (NP (JJ:[115..124] pulmonary)
             (NN:[126..136] cytochrome) (NN:[137..142] P-450)))))
    (.:[142..143] .)))

;section 2 Span:147..173
;Verschoyle RD, Dinsdale D.
(SEC
  (FRAG (NNP:[147..157] Verschoyle) (NNP:[158..160] RD) (,:[160..161] ,)
        (NNP:[162..170] Dinsdale) (NNP:[171..173] D.)))

;section 3 Span:177..260
;MRC Toxicology Unit, Medical Research Council Laboratories, Carshalton
;Surrey,  UK.
(SEC
  (FRAG (NNP:[177..180] MRC) (NNP:[181..191] Toxicology) (NNP:[192..196] Unit)
        (,:[196..197] ,) (NNP:[198..205] Medical) (NNP:[206..214] Research)
        (NNP:[215..222] Council) (NNP:[223..235] Laboratories) (,:[235..236] ,)
        (NNP:[237..247] Carshalton) (NNP:[248..254] Surrey) (,:[254..255] ,)
        (NNP:[257..260] UK.)))

;sentence 4 Span:264..506
;Protection afforded by trialkyl phosphorothionates against the lung injury 
;caused by trialkyl phosphorothiolates probably results from the inhibition by
; the P = S moiety of the thionates, of one or more pulmonary cytochrome P-450
; isozymes.
;[287..314]:substance:"trialkyl phosphorothionates"
;[350..377]:substance:"trialkyl phosphorothiolates"
;[443..452]:substance:"thionates"
;[479..505]:cyp450:"cytochrome P-450  isozymes"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[264..274] Protection))
      (VP (VBN:[275..283] afforded)
        (NP (-NONE-:[283..283] *))
        (PP (IN:[284..286] by)
          (NP-LGS (NN:[287..295] trialkyl) (NNS:[296..314] phosphorothionates))))
      (PP (IN:[315..322] against)
        (NP
          (NP (DT:[323..326] the) (NN:[327..331] lung) (NN:[332..338] injury))
          (VP (VBN:[340..346] caused)
            (NP (-NONE-:[346..346] *))
            (PP (IN:[347..349] by)
              (NP-LGS (NN:[350..358] trialkyl)
                      (NNS:[359..377] phosphorothiolates)))))))
    (ADVP (RB:[378..386] probably))
    (VP (VBZ:[387..394] results)
      (PP-CLR (IN:[395..399] from)
        (NP
          (NP (DT:[400..403] the) (NN:[404..414] inhibition))
          (PP (IN:[415..417] by)
            (NP
              (NP (DT:[419..422] the)
                (NML (NN:[423..424] P) (SYM:[425..426] =) (NN:[427..428] S))
                (NN:[429..435] moiety))
              (PP (IN:[436..438] of)
                (NP (DT:[439..442] the) (NNS:[443..452] thionates)))))
          (,:[452..453] ,)
          (PP (IN:[454..456] of)
            (NP
              (QP (CD:[457..460] one) (CC:[461..463] or) (JJR:[464..468] more))
              (JJ:[469..478] pulmonary)
              
              (NML (NN:[479..489] cytochrome) (NN:[490..495] P-450))
              (NNS:[497..505] isozymes))))))
    (.:[505..506] .)))

;sentence 5 Span:507..656
;The aromatic hydrocarbons p-xylene and pseudocumene also protect  against
;this injury and inhibit some P-450 isozymes, but by a different  mechanism.
;[511..532]:substance:"aromatic hydrocarbons"
;[533..541]:substance:"p-xylene"
;[546..558]:substance:"pseudocumene"
;[610..624]:cyp450:"P-450 isozymes"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[507..510] The)
         (JJ:[511..519] aromatic) (NNS:[520..532] hydrocarbons))
      (NP (NN:[533..541] p-xylene) (CC:[542..545] and)
          (NN:[546..558] pseudocumene)))
    (ADVP (RB:[559..563] also))
    (VP
      (VP (VBP:[564..571] protect)
        (PP-CLR (IN:[573..580] against)
          (NP (DT:[581..585] this) (NN:[586..592] injury))))
      (CC:[593..596] and)
      (VP (VBP:[597..604] inhibit)
        (NP (DT:[605..609] some)
           (NN:[610..615] P-450) (NNS:[616..624] isozymes)))
      (,:[624..625] ,)
      (NAC (CC:[626..629] but)
        (PP-MNR (IN:[630..632] by)
          (NP (DT:[633..634] a) (JJ:[635..644] different)
              (NN:[646..655] mechanism)))))
    (.:[655..656] .)))

;sentence 6 Span:657..902
;OOS-Trimethylphosphorothionate and p-xylene were compared as  protective
;agents against the effect of OOS-trimethylphosphorothiolate and two  other
;lung toxins ipomeanol and 1-nitronaphthalene that are known to be  activated
;by cytochrome P-450.
;[657..687]:substance:"OOS-Trimethylphosphorothionate"
;[692..700]:substance:"p-xylene"
;[730..736]:substance:"agents"
;[759..789]:substance:"OOS-trimethylphosphorothiolate"
;[810..816]:substance:"toxins"
;[817..826]:substance:"ipomeanol"
;[831..849]:substance:"1-nitronaphthalene"
;[885..901]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ-2 (NN:[657..687] OOS-Trimethylphosphorothionate) (CC:[688..691] and)
              (NN:[692..700] p-xylene))
    (VP (VBD:[701..705] were)
      (VP (VBN:[706..714] compared)
        (NP-2 (-NONE-:[714..714] *))
        (PP (IN:[715..717] as)
          (NP
            (NP (JJ:[719..729] protective) (NNS:[730..736] agents))
            (PP (IN:[737..744] against)
              (NP
                (NP (DT:[745..748] the) (NN:[749..755] effect))
                (PP (IN:[756..758] of)
                  (NP
                    (NP (NN:[759..789] OOS-trimethylphosphorothiolate))
                    (CC:[790..793] and)
                    (NP
                      (NP
                        (NP (CD:[794..797] two) (JJ:[799..804] other)
                            (NN:[805..809] lung) (NNS:[810..816] toxins))
                        (NP (NN:[817..826] ipomeanol) (CC:[827..830] and)
                            (NN:[831..849] 1-nitronaphthalene)))
                      (SBAR
                        (WHNP-1 (WDT:[850..854] that))
                        (S
                          (NP-SBJ-1 (-NONE-:[854..854] *T*))
                          (VP (VBP:[855..858] are)
                            (VP (VBN:[859..864] known)
                              (S
                                (NP-SBJ-1 (-NONE-:[864..864] *))
                                (VP (TO:[865..867] to)
                                  (VP (VB:[868..870] be)
                                    (VP (VBN:[872..881] activated)
                                      (NP-1 (-NONE-:[881..881] *))
                                      (PP (IN:[882..884] by)
                                        (NP-LGS (NN:[885..895] cytochrome)
                                                (NN:[896..901] P-450))))))))))))))))))))
    (.:[901..902] .)))

;sentence 7 Span:903..1016
;The effects of these protective compounds, in  vivo, on pulmonary cytochrome
;P-450 activity were also determined.
;[935..944]:substance:"compounds"
;[969..985]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[903..906] The) (NNS:[907..914] effects))
      (PP (IN:[915..917] of)
        (NP (DT:[918..923] these) (JJ:[924..934] protective)
            (NNS:[935..944] compounds)))
      (,:[944..945] ,)
      (ADVP (FW:[946..948] in) (FW:[950..954] vivo))
      (,:[954..955] ,)
      (PP (IN:[956..958] on)
        (NP (JJ:[959..968] pulmonary)
          (NML (NN:[969..979] cytochrome) (NN:[980..985] P-450))
          (NN:[986..994] activity))))
    (VP (VBD:[995..999] were)
      (ADVP (RB:[1000..1004] also))
      (VP (VBN:[1005..1015] determined)
        (NP-1 (-NONE-:[1015..1015] *))))
    (.:[1015..1016] .)))

;sentence 8 Span:1017..1121
;Both  compounds inhibited pentoxyresorufin O-deethylase activity, but not 
;ethoxyresorufin O-deethylase.
;[1023..1032]:substance:"compounds"
;[1043..1072]:substance:"pentoxyresorufin O-deethylase"
;[1092..1120]:substance:"ethoxyresorufin O-deethylase"
(SENT
  (S
    (NP-SBJ (DT:[1017..1021] Both) (NNS:[1023..1032] compounds))
    (VP (VBD:[1033..1042] inhibited)
      (NP
        (NP
          (NML (NN:[1043..1059] pentoxyresorufin) (NN:[1060..1072] O-deethylase))
          (NML-1 (NN:[1073..1081] activity)))
        (,:[1081..1082] ,)
        (CONJP (CC:[1083..1086] but) (RB:[1087..1090] not))
        (NP
          (NML (NN:[1092..1107] ethoxyresorufin) (NN:[1108..1120] O-deethylase))
          (NML-1 (-NONE-:[1120..1120] *P*)))))
    (.:[1120..1121] .)))

;sentence 9 Span:1122..1301
;The phosphorothionate was most effective against  lung injury caused by the
;phosphorothiolates and 1-nitronaphthalene, whereas  p-xylene was much more
;effective against ipomeanol.
;[1126..1143]:substance:"phosphorothionate"
;[1198..1216]:substance:"phosphorothiolates"
;[1221..1239]:substance:"1-nitronaphthalene"
;[1250..1258]:substance:"p-xylene"
;[1291..1300]:substance:"ipomeanol"
(SENT
  (S
    (NP-SBJ (DT:[1122..1125] The) (NN:[1126..1143] phosphorothionate))
    (VP (VBD:[1144..1147] was)
      (ADJP-PRD (RBS:[1148..1152] most) (JJ:[1153..1162] effective)
        (PP (IN:[1163..1170] against)
          (NP
            (NP (NN:[1172..1176] lung) (NN:[1177..1183] injury))
            (VP (VBN:[1184..1190] caused)
              (NP (-NONE-:[1190..1190] *))
              (PP (IN:[1191..1193] by)
                (NP-LGS
                  (NP (DT:[1194..1197] the)
                      (NNS:[1198..1216] phosphorothiolates))
                  (CC:[1217..1220] and)
                  (NP (NN:[1221..1239] 1-nitronaphthalene)))))))))
    (,:[1239..1240] ,)
    (SBAR-ADV (IN:[1241..1248] whereas)
      (S
        (NP-SBJ (NN:[1250..1258] p-xylene))
        (VP (VBD:[1259..1262] was)
          (ADJP-PRD
            (ADVP (RB:[1263..1267] much) (RBR:[1268..1272] more))
            (JJ:[1273..1282] effective)
            (PP (IN:[1283..1290] against)
              (NP (NN:[1291..1300] ipomeanol)))))))
    (.:[1300..1301] .)))

;sentence 10 Span:1302..1538
;beta-Naphthoflavone, which  induces pulmonary ethoxyresorufin O-deethylase
;activity, did not protect against  phosphorothiolate or 1-nitronaphthalene
;injury, and it was only marginally  effective in decreasing the toxicity of
;ipomeanol.
;[1302..1321]:substance:"beta-Naphthoflavone"
;[1348..1376]:substance:"ethoxyresorufin O-deethylase"
;[1412..1429]:substance:"phosphorothiolate"
;[1433..1451]:substance:"1-nitronaphthalene"
;[1528..1537]:substance:"ipomeanol"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[1302..1321] beta-Naphthoflavone))
        (,:[1321..1322] ,)
        (SBAR
          (WHNP-2 (WDT:[1323..1328] which))
          (S
            (NP-SBJ-2 (-NONE-:[1328..1328] *T*))
            (VP (VBZ:[1330..1337] induces)
              (NP (JJ:[1338..1347] pulmonary)
                (NML (NN:[1348..1363] ethoxyresorufin)
                     (NN:[1364..1376] O-deethylase))
                (NN:[1377..1385] activity))))))
      (,:[1385..1386] ,)
      (VP (VBD:[1387..1390] did) (RB:[1391..1394] not)
        (VP (VB:[1395..1402] protect)
          (PP (IN:[1403..1410] against)
            (NP
              (NP (NN:[1412..1429] phosphorothiolate)
                (NML-1 (-NONE-:[1429..1429] *P*)))
              (CC:[1430..1432] or)
              (NP (NN:[1433..1451] 1-nitronaphthalene)
                (NML-1 (NN:[1452..1458] injury))))))))
    (,:[1458..1459] ,) (CC:[1460..1463] and)
    (S
      (NP-SBJ (PRP:[1464..1466] it))
      (VP (VBD:[1467..1470] was)
        (ADJP-PRD
          (ADVP (RB:[1471..1475] only) (RB:[1476..1486] marginally))
          (JJ:[1488..1497] effective))
        (PP (IN:[1498..1500] in)
          (S-NOM
            (NP-SBJ (-NONE-:[1500..1500] *))
            (VP (VBG:[1501..1511] decreasing)
              (NP
                (NP (DT:[1512..1515] the) (NN:[1516..1524] toxicity))
                (PP (IN:[1525..1527] of)
                  (NP (NN:[1528..1537] ipomeanol)))))))))
    (.:[1537..1538] .)))

;section 11 Span:1542..1586
;PMID: 2384072 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1542..1546] PMID) (::[1546..1547] :) (CD:[1548..1555] 2384072)
        (NN:[1556..1557] -LSB-) (NNP:[1557..1563] PubMed) (::[1564..1565] -)
        (NN:[1566..1573] indexed) (IN:[1574..1577] for)
        (NNP:[1578..1586] MEDLINE-RSB-)))
